Answers are grounded in this paper and cite their sources.
In the phase II BECOME study, Becotarug (Beco) combined with Osi showed promising efficacy and manageable safety in platinum-pretreated EGFR ex20ins-positive NSCLC (ELCC 2024, 137MO). Here, we report the final OS analyses and subgroup efficacy results.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: